Revised SPC: Neulasta (pegfilgrastim) products

SPC now includes data from post-marketing observational study of pegfilgrastim in conjunction with chemotherapy and/or radiotherapy showing link to development of myelodysplastic syndrome and acute myeloid leukaemia in breast and lung cancer patients.

Source:

electronic Medicines compendium